marketcaparena
Search

    Seer, Inc.

    SEER

    Trailing 12 months YoY growth · margin

    Revenue
    —
    Gross profit
    —
    Operating income
    —
    Free cash flow
    —
    Employees 124Company website
    About Seer, Inc.

    Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company also offers Proteograph ONE, a third-generation assay; Proteograph DIRECT, which provides an automated approach for direct digestion of samples for bottom-up LC-MS proteomic analysis; and Proteograph Analysis Suite, a data analytics software suite designed to support quality control, data management, and interpretation of Proteograph output which is currently offered as a cloud-based solution. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

    Market data

    Share price

    Daily close · USD

    $2.15
    −2.71%$118Mmarket cap

    Historical closing prices; only dates with recorded USD source data are available.

    Against the benchmark

    Rebased to 100

    Rebased adjusted prices on matching dates. This is not a total-return comparison.

    Operating metrics

    The measures behind the business.

    No operating metrics are currently published for this company.

    Revenue mix

    What the company sells, and where.

    Revenue by product

    Q4 25 · USD

    $128KOther

    Reported categories are shown independently; no total or percentage is inferred.

    Product growth

    Q4 24 to Q4 25

    Same fiscal period one year apart.

    Revenue by product

    FY 25 · USD

    $459KOther

    Reported categories are shown independently; no total or percentage is inferred.

    Product growth

    FY 24 to FY 25

    Same fiscal period one year apart.

    Income statement

    From revenue to profit.

    Income reporting period

    Revenue

    Quarterly · USD

    $3.1MQ2 26

    Revenue and profit

    Quarterly · USD

    From revenue to net income

    Q2 26 · USD

    $-16.9MNet income

    Hatched marks are outflows or deductions. Reconciliation differences are calculated, not separately reported categories.

    Cash flow

    Cash generated and cash spent.

    Cash flow reporting period

    Free cash flow

    Quarterly · USD

    $-15.7MQ1 26

    Operating cash flow plus signed capital expenditures; both inputs must be available for the same period.

    Operating cash flow

    Quarterly · USD

    $-15.4MQ1 26

    Cash movements

    Q1 26 · USD

    $33KChange in cash

    Hatched marks are outflows or deductions. Reconciliation differences are calculated, not separately reported categories.

    Free cash flow

    YTD · USD

    $-25.3MQ2 26

    Operating cash flow plus signed capital expenditures; both inputs must be available for the same period.

    Operating cash flow

    YTD · USD

    $-25MQ2 26

    Cash movements

    Q2 26 · USD

    $-21.2MChange in cash

    Hatched marks are outflows or deductions. Reconciliation differences are calculated, not separately reported categories.

    Balance sheet

    What the company owns and what it owes.

    Balance sheet reporting period

    Cash and short-term investments

    Quarterly · USD

    Both components must be reported for the period.

    Balance sheet

    Q2 26 · USD

    Remaining assets and liabilities are calculated differences after the shown components. Ingestion selects and reconciles these components; exact source values are retained.

    Financial statements

    Every published field, with exact amounts and disclosure sources.

    View full financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USD
    Total Revenue3,102,000USD2,793,000USD
    Cost Of Revenue1,596,000USD1,811,000USD
    Gross Profit1,506,000USD982,000USD
    Research Development8,209,000USD8,806,000USD
    Selling General Administrative10,138,000USD9,432,000USD
    Total Operating Expenses18,347,000USD18,238,000USD
    Operating Income-16,841,000USD-17,256,000USD
    Total Other Income Expense Net-49,000USD429,000USD
    Interest Income2,052,000USD2,225,000USD
    Labor And Related Expense7,172,000USD7,712,000USD
    Income Before Tax-16,890,000USD-16,827,000USD
    Income Tax Expense9,000USD10,000USD
    Equity Method Income Loss-2,088,000USD-1,728,000USD
    Net Income-16,899,000USD-16,837,000USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinal

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USD
    Total Assets256,638,000USD272,132,000USD
    Cash And Equivalents26,075,000USD47,318,000USD
    Total Current Assets166,098,000USD181,593,000USD
    Other Non Current Assets1,927,000USD3,792,000USD
    Total Liabilities30,958,000USD30,653,000USD
    Total Current Liabilities11,267,000USD10,243,000USD
    Other Current Liabilities22,000USD38,000USD
    Other Non Current Liabilities15,000USD26,000USD
    Total Stockholder Equity225,680,000USD241,479,000USD
    Total Equity Including Noncontrolling Interest225,680,000USD241,479,000USD
    Deferred Revenue372,000USD334,000USD
    Inventory7,663,000USD8,079,000USD
    Property Plant Equipment Net31,458,000USD33,375,000USD
    Short Term Debt2,714,000USD2,644,000USD
    Retained Earnings-499,708,000USD-482,809,000USD
    Accumulated Other Comprehensive Income-336,000USD-64,000USD
    Cash And Short Term Investments—219,500,000USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinal

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation2,276,000USD
    Stock Based Compensation3,691,000USD
    Change To Account Receivables2,520,000USD
    Change To Inventory157,000USD
    Change To Liabilities-2,626,000USD
    Change In Working Capital-126,000USD
    Operating Cash Flow-25,006,000USD
    Capital Expenditures-279,000USD
    Net Investments8,603,000USD
    Unclassified Investing Cash Flow-1,715,000USD
    Investing Cash Flow6,609,000USD
    Financing Cash Flow-2,813,000USD
    Change In Cash-21,210,000USD
    End Cash Flow26,599,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USD
    Net Income-16,837,000USD
    Stock Based Compensation2,127,000USD
    Other Non Cash Items-10,000USD
    Unclassified Operating Cash Flow1,632,000USD
    Change To Account Receivables1,696,000USD
    Change To Inventory-378,000USD
    Change To Liabilities-3,005,000USD
    Change In Working Capital-2,347,000USD
    Operating Cash Flow-15,435,000USD
    Capital Expenditures-270,000USD
    Net Investments19,805,000USD
    Unclassified Investing Cash Flow-1,459,000USD
    Investing Cash Flow18,076,000USD
    Financing Cash Flow-2,608,000USD
    Change In Cash33,000USD
    End Cash Flow47,842,000USD
    SourceDisclosureDeterministicFinal

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. TTM requires four complete quarters. Missing values are not zero. Charts use rounded labels; financial statement tables retain exact amounts. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.